Asarina Pharma AB (OSTO:ASAP) EBIT : kr-14.53 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Asarina Pharma AB EBIT?

Asarina Pharma AB's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was kr-5.09 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-14.53 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Asarina Pharma AB's annualized ROC % for the quarter that ended in Dec. 2023 was -192.15%. Asarina Pharma AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1,128.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Asarina Pharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1,169.57%.

Asarina Pharma AB EBIT Historical Data

The historical data trend for Asarina Pharma AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB EBIT Chart

Asarina Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-78.63

-82.79

-37.90

-14.53

Asarina Pharma AB Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial									-15.59	-7.82	-6.71	-9.44	-5.09

Competitive Comparison of Asarina Pharma AB's EBIT

For the Biotechnology subindustry, Asarina Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asarina Pharma AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asarina Pharma AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Asarina Pharma AB's EV-to-EBIT falls into.

Asarina Pharma AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-14.53 Mil.

Asarina Pharma AB (OSTO:ASAP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Asarina Pharma AB's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-10.23 * ( 1 - 34.38% )	/	( (2.407	+	4.58)	/ 2 )
=	-6.712926	/	3.4935
=	-192.15 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.906	-	1.101	-	( 4.729	-	max(0, 2.48	-	6.878	+	4.729	))
=	2.407

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.077	-	0.626	-	( 3.161	-	max(0, 4.426	-	5.297	+	3.161	))
=	4.58

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Asarina Pharma AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-10.178	/	( ( (1.026 + max(-0.811, 0))	+	(0.778 + max(-1.617, 0)) )	/	2 )
=	-10.178	/	( ( 1.026	+	0.778 )	/	2 )
=	-10.178	/	0.902
=	-1,128.38 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.669)	-	(1.101	+	0	+	1.379)
=	-0.811

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.809)	-	(0.626	+	0	+	2.8)
=	-1.617

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Asarina Pharma AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-14.526	/	-1.242
	=	1,169.57 %

Asarina Pharma AB EBIT Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Asarina Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (OSTO:ASAP) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65

Website

https://www.asarinapharma.com

Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB Headlines

No Headlines